What does SAUSSURE PHARMA do?

SAUSSURE PHARMA is a pharmacy in Beauraing. Private Limited, started on 27 December 2019, 1 establishment.

What is the address of SAUSSURE PHARMA?

The registered office of SAUSSURE PHARMA is located at rue de Rochefort 122, 5570 Beauraing.

Is SAUSSURE PHARMA still active?

Yes. According to the CBE (30 October 2026) SAUSSURE PHARMA is active, legal situation “Normale toestand”, started on 27 December 2019.

Is SAUSSURE PHARMA registered on Peppol?

Yes, SAUSSURE PHARMA is registered on the Peppol network with ID 0208:0740545114.

What is the enterprise number of SAUSSURE PHARMA?

The enterprise number of SAUSSURE PHARMA is BE0740545114.

When was SAUSSURE PHARMA founded?

SAUSSURE PHARMA was founded on 27 December 2019.

Who are the directors of SAUSSURE PHARMA?

According to the 2025 annual accounts, the directors of SAUSSURE PHARMA are: PIERRE DEJARDIN.

Is SAUSSURE PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 December 2019; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SAUSSURE PHARMA make in 2025?

SAUSSURE PHARMA posted a profit after taxes of € 9,410 in financial year 2025.

What is the revenue of SAUSSURE PHARMA?

As a small company, SAUSSURE PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 46,727.

SAUSSURE PHARMA (Private Limited) - Beauraing

Dossier SAUSSURE PHARMA, printed on 30 October 2026 from databakkes.be/en/0740545114/saussure-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

SAUSSURE PHARMA from Beauraing, company number BE0740545114, closed financial year 2025 with a result of € 9,410 after tax. For that financial year SAUSSURE PHARMA recorded a gross margin of € 46,727 and equity of € 54,488. Compared with financial year 2024, the result moved from € 9,927 to € 9,410. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.

What it is worth Growing

€ 54,488

▲ 21% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 9,410

▼ 5% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 34,568

▼ 7% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 44,488.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 204,427

▼ 16% vs 2024

€ 39,297 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 244,854

▲ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,606

▲ 62% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 38,165 Gross margin 2022: € 38,165 First fiscal year in the series	€ 49,125 Gross margin 2023: € 49,125 ▲ 29% vs 2022 (€ 38,165) Favourable step	€ 47,892 Gross margin 2024: € 47,892 ▼ 3% vs 2023 (€ 49,125) Unfavourable step	€ 46,727 Gross margin 2025: € 46,727 ▼ 2% vs 2024 (€ 47,892) Unfavourable step	▼ 2%
Profit after taxes	€ 950 Profit after taxes 2022: € 950 First fiscal year in the series	€ 8,841 Profit after taxes 2023: € 8,841 ▲ € 7,890 vs 2022 (€ 950) Favourable step	€ 9,927 Profit after taxes 2024: € 9,927 ▲ 12% vs 2023 (€ 8,841) Favourable step	€ 9,410 Profit after taxes 2025: € 9,410 ▼ 5% vs 2024 (€ 9,927) Unfavourable step	▼ 5%
Equity	€ 26,310 Equity 2022: € 26,310 First fiscal year in the series	€ 35,150 Equity 2023: € 35,150 ▲ 34% vs 2022 (€ 26,310) Favourable step	€ 45,078 Equity 2024: € 45,078 ▲ 28% vs 2023 (€ 35,150) Favourable step	€ 54,488 Equity 2025: € 54,488 ▲ 21% vs 2024 (€ 45,078) Favourable step	▲ 21%
Total debts	€ 505,814 Total debts 2022: € 505,814 First fiscal year in the series	€ 522,914 Total debts 2023: € 522,914 ▲ 3% vs 2022 (€ 505,814) Unfavourable step	€ 475,084 Total debts 2024: € 475,084 ▼ 9% vs 2023 (€ 522,914) Favourable step	€ 455,180 Total debts 2025: € 455,180 ▼ 4% vs 2024 (€ 475,084) Favourable step	▼ 4%
Cash	€ 60,808 Cash 2022: € 60,808 First fiscal year in the series	€ 60,028 Cash 2023: € 60,028 ▼ 1% vs 2022 (€ 60,808) Unfavourable step	€ 37,362 Cash 2024: € 37,362 ▼ 38% vs 2023 (€ 60,028) Unfavourable step	€ 34,568 Cash 2025: € 34,568 ▼ 7% vs 2024 (€ 37,362) Unfavourable step	▼ 7%
Retained profit	€ 16,310 Retained profit 2022: € 16,310 First fiscal year in the series	€ 25,150 Retained profit 2023: € 25,150 ▲ 54% vs 2022 (€ 16,310) Favourable step	€ 35,078 Retained profit 2024: € 35,078 ▲ 39% vs 2023 (€ 25,150) Favourable step	€ 44,488 Retained profit 2025: € 44,488 ▲ 27% vs 2024 (€ 35,078) Favourable step	▲ 27%
Bank debt	€ 323,162 Bank debt 2022: € 323,162 First fiscal year in the series	€ 281,848 Bank debt 2023: € 281,848 ▼ 13% vs 2022 (€ 323,162) Favourable step	€ 243,333 Bank debt 2024: € 243,333 ▼ 14% vs 2023 (€ 281,848) Favourable step	€ 204,427 Bank debt 2025: € 204,427 ▼ 16% vs 2024 (€ 243,333) Favourable step	▼ 16%
Balance sheet total	€ 532,123 Balance sheet total 2022: € 532,123 First fiscal year in the series	€ 558,064 Balance sheet total 2023: € 558,064 ▲ 5% vs 2022 (€ 532,123) Unchanged	€ 520,162 Balance sheet total 2024: € 520,162 ▼ 7% vs 2023 (€ 558,064) Unchanged	€ 509,667 Balance sheet total 2025: € 509,667 ▼ 2% vs 2024 (€ 520,162) Unchanged	▼ 2%

Key figures of SAUSSURE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SAUSSURE PHARMA?

What happened at SAUSSURE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 8, 2026 New annual accounts for financial year 2025: profit of € 9,410 (▼ 5% vs 2024). Source: NBB ↗
Dec 27, 2020 New establishment in Paliseul. KBO
Dec 27, 2019 Start of the company according to the CBE. KBO

In short

From € 950 profit in 2022 to € 9,410 profit in 2025.

Paid € 10,141 in corporate taxes since 2022.

Best year ever: 2024, with € 9,927 profit.

Original PDFs at the National Bank ↗

Management

PIERRE DEJARDIN

SAUSSURE PHARMA

Pharmacie dejardin

PHARMACIE ELSEN

PHARMACIE SAINTE-ANNE

Behind SAUSSURE PHARMA is PIERRE DEJARDIN. PIERRE DEJARDIN is also behind Pharmacie dejardin, PHARMACIE ELSEN and PHARMACIE SAINTE-ANNE.

Directors

According to the 2025 annual accounts

PIERRE DEJARDIN

Director

Also active at: Pharmacie dejardin, PHARMACIE ELSEN, PHARMACIE SAINTE-ANNE

Establishments

Establishment units

Physical locations of this company

Registered office

rue de Rochefort 122

5570 Beauraing

2.301.040.829

Rue Emile-Gardez, Carlsbourg 2

6850 Paliseul

Active since 27 December 2020

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

Pharmacie dejardin same network

€ 348,751 gross margin · 2025

GE DEJARDIN

€ 732,155 gross margin · 2025

DEJARDIN INVEST SRL

€ 282,993 gross margin · 2025

Unité TVA GROUPE DEJARDIN

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0740.545.114
VAT number: BE 0740.545.114
Registered office: rue de Rochefort 122, 5570 Beauraing
Names & denominations: SAUSSURE PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 December 2019
Peppol: Active · Active since 18 Dec 2025
Contact: [email protected] +32474599819
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗